A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
RJ Amato, J Jac, S Giessinger, S Saxena, JP Willis - Cancer, 2009 - Wiley Online Library
BACKGROUND: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor,
affects tumor growth by blocking growth factor stimulation, arresting cell cycle progression …
affects tumor growth by blocking growth factor stimulation, arresting cell cycle progression …
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma …
Background Activation of the mammalian target of rapamycin (mTOR) pathway is observed
in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that …
in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that …
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
MM Javle, RT Shroff, H Xiong, GA Varadhachary… - BMC cancer, 2010 - Springer
Background The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in
pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important …
pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important …
mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors
Although agents that inhibit specific oncogenic kinases have been successful in a subset of
cancers, there are currently few treatment options for malignancies that lack a targetable …
cancers, there are currently few treatment options for malignancies that lack a targetable …
Pushing the envelope in the mTOR pathway: the second generation of inhibitors
E Vilar, J Perez-Garcia, J Tabernero - Molecular cancer therapeutics, 2011 - AACR
Abstract The phosphatidylinositol-3-kinase (PI3K)/mTOR pathway has been a major focus of
attention for cancer researchers in the past decade. A preliminary and incomplete …
attention for cancer researchers in the past decade. A preliminary and incomplete …
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based …
C Saura, J Bendell, G Jerusalem, S Su, Q Ru… - Clinical Cancer …, 2014 - AACR
Abstract Purpose: Phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway activation in
patients with HER2-positive (HER2+) breast cancer has been implicated in de novo and …
patients with HER2-positive (HER2+) breast cancer has been implicated in de novo and …
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014
Purpose: AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo
efficacy across a range of preclinical human cancer models. Experimental Design: A rolling …
efficacy across a range of preclinical human cancer models. Experimental Design: A rolling …
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
J Roper, MP Richardson, WV Wang, LG Richard… - PloS one, 2011 - journals.plos.org
Purpose To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-
BEZ235 in treatment of PIK3CA wild-type colorectal cancer (CRC). Experimental Design …
BEZ235 in treatment of PIK3CA wild-type colorectal cancer (CRC). Experimental Design …
TAK‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple …
The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human
cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and …
cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and …
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis
PF McAuliffe, F Meric-Bernstam, GB Mills… - Clinical breast …, 2010 - Elsevier
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression …
(mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression …